Dr Lal PathLabs Delivers ₹509 Cr FY26 Profit, Eyes Expansion with SDCPL Buy and Dubai Unit

Dr. Lal PathLabs Ltd. announced strong audited financial results for the fiscal year ending March 31, 2026. The company reported consolidated revenue of ₹2,864.20 crore and a consolidated profit after tax (PAT) of ₹509.80 crore for the full year. For the fourth quarter of FY26, revenue reached ₹726.70 crore with PAT at ₹132.20 crore, underscoring the company's operational strength.

The company also revealed significant strategic expansion plans. It intends to acquire a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL) for up to ₹20 crore, a move designed to strengthen its presence in Mumbai and Maharashtra. Additionally, Dr. Lal PathLabs will establish a new wholly-owned subsidiary in Dubai, United Arab Emirates, to pursue strategic international investments and potential acquisitions in the diagnostics sector.

The acquisition of SDCPL, which had a FY26 turnover of ₹6.11 crore, signals Dr. Lal PathLabs' commitment to consolidating and expanding its domestic footprint in key markets. The Dubai subsidiary marks a clear step towards international growth and diversification, enhancing the company's global reach.

These initiatives follow previous strategic moves. The company recently completed the integration phase of its large acquisition of Suburban Diagnostics, acquired in October 2021. Earlier, in September 2025, Dr. Lal PathLabs announced plans to acquire immovable property in New Delhi for up to ₹74.51 crore to support its network expansion.

Shareholders are set to benefit from the Board's recommendation of a final dividend of ₹4 per equity share for FY25-26, pending approval at the Annual General Meeting.

However, several points require attention. The SDCPL acquisition is slated for completion by May 31, 2026, and is subject to regulatory approvals. The final dividend also needs member approval at the AGM on July 25, 2026. In a separate matter, a Delhi Consumer Commission ruling in May 2025 upheld a penalty against the company related to a faulty diagnostic report from 2011. Furthermore, the healthcare sector's ongoing data security concerns were highlighted by a significant data breach in October 2020 that exposed millions of customer records.

In comparison, Dr. Lal PathLabs' FY26 consolidated revenue was ₹2,864.20 crore and PAT was ₹509.80 crore. Key peers include Apollo Hospitals' diagnostics revenue (₹1,278 million in Q4 FY25), Max Healthcare's diagnostics arm revenue (₹54 crore in Q2 FY26), and Agilus Diagnostics' revenue (₹1,139 crore in 9M-FY26).

Looking at growth trends, Dr. Lal PathLabs' consolidated revenue grew from ₹2,016.9 crore in FY23 to ₹2,864.20 crore in FY26. Consolidated PAT also increased significantly, from ₹241.1 crore in FY23 to ₹509.80 crore in FY26 over the same period.

Investors will be tracking the completion of the SDCPL acquisition and subsequent integration, shareholder approval for the dividend, and the strategic progress of the Dubai subsidiary. Monitoring the financial impact of these moves and any further developments from regulatory or operational fronts will be key.